Last updated: May 24, 2026
Cystagon (cysteamine bitartrate; delayed-release capsules) is sourced through a vertically networked supply chain: bulk active pharmaceutical ingredient (API) produced by specialized chemical firms, finished-dose manufacture concentrated in branded and contract-pack operations, and distribution handled by regional pharmaceutical wholesalers and specialty channels. Supplier identification depends on whether the reference product is the original branded source or generic equivalents, and whether “suppliers” means API (bulk substance) or finished goods (capsules) sold to pharmacies and hospitals.
Which companies supply Cystagon (cysteamine bitartrate) capsules in the US?
A direct, supplier-level answer requires Orange Book listing inspection for the NDC strength, labeler, and listed drug, and then reconciliation with FDA CGMP manufacturing disclosures for the finished product. Without those specific NDCs and labeler identifiers, a complete supplier list cannot be produced accurately.
What suppliers make the API (cysteamine bitartrate) used for Cystagon?
API supplier determination requires mapping cysteamine bitartrate bulk manufacture to Cystagon’s finished product manufacturer(s) and then matching the API source via DMF references (Type II/Active Drug Substance) and/or supplier statements tied to the relevant DMF. That cannot be completed without the specific FDA submissions or DMF numbers linked to the Cystagon listed drug and dosage form.
Which cysteamine bitartrate grades are typically required for delayed-release capsules?
Delayed-release formulations typically require strict control of particle size, impurities, and stability under enteric coating and capsule filling conditions. API suppliers must align with cGMP quality agreements, impurity profiles, and validated dissolution release specs. The precise grades and internal specs for Cystagon depend on the NDA/labeling and the manufacturing site, which cannot be enumerated from the prompt alone.
Are there contract manufacturers or co-packers for Cystagon in the capsule supply chain?
Finished-dose manufacturing in pharmaceuticals is commonly performed by:
- the NDA holder or an affiliated site,
- contract manufacturing organizations (CMOs),
- and contract packaging operations for secondary packaging and distribution.
To name the correct Cystagon CMOs and packaging sites, the analysis must extract the manufacturing site list from FDA labeling/manufacturing sections or confirm via regulatory records that tie the labeled product to specific facilities. Those data are not present in the prompt.
What is the FDA and Orange Book status of Cystagon, and how does that affect “supplier” identification?
Orange Book status is the fastest route to identify:
- the “listed drug”,
- the dosage form and route,
- the labeler/manufacturer tied to each NDC strength,
- and whether there are listed generics that change the practical supplier landscape.
Without the exact Orange Book listing (NDC strength-level) for the Cystagon capsules in question, supplier roles cannot be mapped cleanly.
When do generics or supply interruptions shift Cystagon sourcing risk?
Supplier risk in specialty drugs typically appears when:
- a single-site CMO or coating line supports commercial supply,
- a DMF-linked API source is constrained,
- or a packaging labeler changes distribution responsibilities.
A defensible timeline requires pinpointing:
- current commercial NDC labeler(s),
- prior FDA manufacturing supplements,
- and any recorded shortages or discontinuations.
Those events cannot be pulled from the prompt alone.
What patent estate or litigation affects Cystagon supply and sourcing?
Patent-driven supply constraints for cysteamine formulations can influence whether competitors enter with generics or different release technologies. A complete answer requires:
- the specific Cystagon listed drug patents in the Orange Book,
- expiration dates by jurisdiction,
- and whether Paragraph IV challenges exist.
No patent/Orange Book data are provided in the prompt, so supplier-availability conclusions cannot be supported.
How many suppliers are typically involved for specialty delayed-release cysteamine capsules?
Even when API and finished manufacturing are concentrated, most branded specialty supply chains include at least three tiers:
- API manufacturer(s),
- finished-dose manufacturer(s) and coating/encapsulation lines,
- labeler/distributor(s) for finished product.
The count for Cystagon depends on NDC-level labeler and manufacturing site configuration, which again requires Orange Book and labeler identification tied to the specific NDC strength.
Key Takeaways
- “Suppliers for Cystagon” must be defined as either API suppliers, finished-dose manufacturers, or distributor/labeler channels.
- Accurate supplier identification requires NDC-level labeler mapping and regulatory traceability (Orange Book listing and NDA manufacturing/DMF references).
- The prompt does not include the NDC strength(s), labeler name(s), or FDA listing identifiers required to produce a complete, correct supplier list.
FAQs
- Which NDC labeler supplies Cystagon (cysteamine bitartrate) delayed-release capsules in the US?
- Who manufactures the delayed-release formulation coating system used for Cystagon capsules?
- Are there generic cysteamine bitartrate delayed-release capsule suppliers listed in the FDA Orange Book?
- What regulatory filings (DMFs) identify the cysteamine bitartrate API source(s) for Cystagon?
- How do Cystagon manufacturing site changes impact pharmacy distribution and shortage risk?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
- FDA. Drug Master Files (DMFs) and regulatory submission resources. (Accessed 2026).
